This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Garvey, M. A. Articles by Swedo, S. E. Search for Related Content PubMed PubMed Citation Articles by Garvey, M. A. Articles by Swedo, S. E. Social Bookmarking                         What's this?

Treatment of Sydenham's Chorea with Intravenous Immunoglobulin, Plasma Exchange, or Prednisone

Pediatrics and Developmental Neuropsychiatry Branch National Institute of Mental Health

Lisa A. Snider, MD

Pediatrics and Developmental Neuropsychiatry Branch National Institute of Mental Health, sniderl{at}intra.nimh.nih.gov

Susan F. Leitman, MD

Department of Transfusion Medicine Warren G. Magnuson Clinical Center, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

Rose Werden, RN

Department of Transfusion Medicine Warren G. Magnuson Clinical Center, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

Susan E. Swedo, MD

Pediatrics and Developmental Neuropsychiatry Branch National Institute of Mental Health

Sydenham's chorea has been established as a postinfectious autoimmune neuropsychiatric disorder. Corticosteroids have been used to treat patients with severe disease but are not always effective, and relapses are frequent after cessation. Eighteen subjects were entered into this randomized-entry controlled trial designed to determine if intravenous immunoglobulin or plasma exchange would be superior to prednisone in decreasing the severity of chorea. Mean chorea severity for the entire group was significantly lower at the 1-month follow-up evaluation (overall 48% improvement). Although the between-group differences were not statistically significant, clinical improvements appeared to be more rapid and robust in the intravenous immunoglobulin and plasma exchange groups than in the prednisone group (mean chorea severity scores decreased by 72% in the intravenous immunoglobulin group, 50% in the plasma exchange group, and 29% in the prednisone group). Larger studies are required to confirm these clinical observations and to determine if these treatments are cost-effective for this disorder. (J Child Neurol 2005;20:424—429).

Journal of Child Neurology, Vol. 20, No. 5, 424-429 (2005)
DOI: 10.1177/08830738050200050601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?